
Jeffrey F Peipert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6485029/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Comprehensive Immediate Postpartum Contraception With Infant Outcomes. JAMA Pediatrics, 2022, 176, 233.	6.2	1
2	Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Network Open, 2022, 5, e2148474.	5.9	14
3	Association of Obesity With Longer Time to Pregnancy. Obstetrics and Gynecology, 2022, 139, 554-560.	2.4	6
4	Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study. American Journal of Obstetrics and Gynecology, 2022, 227, 57.e1-57.e13.	1.3	4
5	Comparison of procedure time between manual and electric vacuum aspiration for pregnancy termination between 10-14 weeks: A randomized trial. Contraception, 2022, 113, 108-112.	1.5	1
6	Sustainable and effective methods to increase longâ€acting reversible contraception uptake from the ACCORd general practice trial. Australian and New Zealand Journal of Public Health, 2022, 46, 540-544.	1.8	2
7	Developing a Youth Contraception Navigator Program: A Human-Centered Design Approach. Journal of Adolescent Health, 2022, , .	2.5	4
8	Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Lancet, The, 2022, 399, 2103-2112.	13.7	13
9	Contraception and ectopic pregnancy risk: a prospective observational analysis. American Journal of Obstetrics and Gynecology, 2021, 224, 228-229.	1.3	9
10	Contraceptive Preference, Continuation Rates, and Unintended Pregnancies in Patients with Comorbidities: A Prospective Cohort Study. Journal of Women's Health, 2021, 30, 1469-1475.	3.3	0
11	Women's satisfaction with and ongoing use of hormonal longâ€acting methods compared to the oral contraceptive pill: Findings from an Australian general practice cluster randomised trial (ACCORd). Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 448-453.	1.0	2
12	Design of the Association of Uterine Perforation and Expulsion of Intrauterine Device study: a multisite retrospective cohort study. American Journal of Obstetrics and Gynecology, 2021, 224, 599.e1-599.e18.	1.3	8
13	Influences on condom use: A secondary analysis of women's perceptions from the Australian Contraceptive ChOice pRoject (ACCORd) trial. Australian Journal of General Practice, 2021, 50, 581-587.	0.8	3
14	Intrauterine device use, sexually transmitted infections, and fertility: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 157.e1-157.e9.	1.3	7
15	Copper intrauterine device and incident sexually transmitted infections. American Journal of Obstetrics and Gynecology, 2021, 225, 579-580.	1.3	2
16	Cost-effectiveness of a complex intervention in general practice to increase uptake of long-acting reversible contraceptives in Australiaâ€. Australian Health Review, 2021, 45, 728-734.	1.1	0
17	Noncandidal vaginitis: a comprehensive approach to diagnosis and management. American Journal of Obstetrics and Gynecology, 2020, 222, 114-122.	1.3	29
18	Associations between the vaginal microbiome and Candida colonization in women of reproductive age. American Journal of Obstetrics and Gynecology, 2020, 222, 471.e1-471.e9.	1.3	52

#	Article	IF	CITATIONS
19	Increasing long-acting reversible contraceptives: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized trial. American Journal of Obstetrics and Gynecology, 2020, 222, S921.e1-S921.e13.	1.3	26
20	Evaluation of a computerized contraceptive decision aid: A randomized controlled trial. Contraception, 2020, 102, 339-345.	1.5	5
21	Increasing the uptake of long-acting reversible contraception in general practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomised controlled trial longitudinal follow-up protocol. BMJ Open, 2020, 10, e035895.	1.9	1
22	Comparison of unintended pregnancy at 12 months between two contraceptive care programs; a controlled time-trend design. Contraception, 2019, 100, 196-201.	1.5	7
23	Association between obesity and bacterial vaginosis as assessed by Nugent score. American Journal of Obstetrics and Gynecology, 2019, 220, 476.e1-476.e11.	1.3	50
24	Effect of staff training and cost support on provision of long-acting reversible contraception in community health centers. Contraception, 2019, 99, 222-227.	1.5	16
25	Dual method use among long-acting reversible contraceptive users. European Journal of Contraception and Reproductive Health Care, 2018, 23, 97-104.	1.5	10
26	Anticipated pain as a predictor of discomfort with intrauterine device placement. American Journal of Obstetrics and Gynecology, 2018, 218, 236.e1-236.e9.	1.3	22
27	Medicaid savings from the Contraceptive CHOICE Project: a cost-savings analysis. American Journal of Obstetrics and Gynecology, 2018, 219, 595.e1-595.e11.	1.3	16
28	Effect of baseline menstrual bleeding pattern on copper intrauterine device continuation. American Journal of Obstetrics and Gynecology, 2018, 219, 465.e1-465.e5.	1.3	3
29	Differences in Contraceptive Discontinuation Among Black and White Women: Evidence from the Contraceptive CHOICE Project. Journal of Women's Health, 2018, 27, 599-606.	3.3	5
30	Lippes loop and the first IUDs: lessons from aÂbygone era. American Journal of Obstetrics and Gynecology, 2018, 219, 127-128.	1.3	4
31	Comparison of an additional early visit to routine postpartum care on initiation of long-acting reversible contraception: A randomized trial. Contraception, 2018, 98, 223-227.	1.5	6
32	From research to practice: dissemination of the Contraceptive CHOICE Project. Translational Behavioral Medicine, 2017, 7, 128-136.	2.4	8
33	Validity of self-reported history of Chlamydia trachomatisÂinfection. American Journal of Obstetrics and Gynecology, 2017, 216, 393.e1-393.e7.	1.3	12
34	Long-Acting Reversible Contraception. New England Journal of Medicine, 2017, 376, 461-468.	27.0	69
35	Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond FoodÂandÂDrug Administration–approved duration. American Journal of Obstetrics and Gynecology, 2017, 216, 586.e1-586.e6.	1.3	82
36	Is It Time to Abandon the Routine Pelvic Examination in Asymptomatic Nonpregnant Women?. JAMA - Journal of the American Medical Association, 2017, 317, 910.	7.4	0

#	Article	IF	CITATIONS
37	Reducing health disparities by removing cost, access, and knowledgeÂbarriers. American Journal of Obstetrics and Gynecology, 2017, 216, 382.e1-382.e5.	1.3	25
38	Long-acting reversible contraception inÂadolescents: a systematic review andÂmeta-analysis. American Journal of Obstetrics and Gynecology, 2017, 216, 364.e1-364.e12.	1.3	89
39	Changes in body composition in women using long-acting reversible contraception. Contraception, 2017, 95, 382-389.	1.5	26
40	Sexually transmitted diseases and infertility. American Journal of Obstetrics and Gynecology, 2017, 216, 1-9.	1.3	282
41	Condom use and incident sexually transmitted infection after initiation of long-acting reversible contraception. American Journal of Obstetrics and Gynecology, 2017, 217, 672.e1-672.e6.	1.3	23
42	Socioeconomic Status As a Risk Factor for Unintended Pregnancy in the Contraceptive CHOICE Project. Obstetrics and Gynecology, 2017, 130, 609-615.	2.4	45
43	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 192-193.	1.3	0
44	Surgical Management of Benign Adnexal Masses in the Pediatric/Adolescent Population: An 11-Year Review. Journal of Pediatric and Adolescent Gynecology, 2017, 30, 123-127.	0.7	31
45	Relationship between nugent score and vaginal epithelial exfoliation. PLoS ONE, 2017, 12, e0177797.	2.5	42
46	Long-acting reversible contraception use among residents in obstetrics/gynecology training programs. Open Access Journal of Contraception, 2017, Volume 8, 1-7.	1.4	8
47	Contraception and Sterilization. , 2017, , 447-460.		0
48	Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. Contraception, 2016, 94, 556-560.	1.5	19
49	Barriers and facilitators to implementing a patient-centered model of contraceptive provision in community health centers. Contraception and Reproductive Medicine, 2016, 1, 21.	1.9	21
50	Management of Benign Adnexal Masses in the Pediatric/Adolescent Population. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 180.	0.7	1
51	Adult Comorbidity Evaluation 27 score as a predictor ofÂsurvival in endometrial cancer patients. American Journal of Obstetrics and Gynecology, 2016, 215, 766.e1-766.e9.	1.3	23
52	Sexual Desire and Hormonal Contraception. Obstetrics and Gynecology, 2016, 127, 563-572.	2.4	48
53	Risk of unintended pregnancy based on intended compared to actual contraceptive use. American Journal of Obstetrics and Gynecology, 2016, 215, 71.e1-71.e6.	1.3	25
54	Eliminating health disparities in unintended pregnancy with long-acting reversible contraception (LARC). American Journal of Obstetrics and Gynecology, 2016, 214, 681-688.	1.3	96

#	Article	IF	CITATIONS
55	Changes in Insurance Status in CHOICE Project Participants. Journal of reproductive medicine, The, 2016, 61, 63-8.	0.2	0
56	Sexual Behavior and Contraceptive Use at Brown University: 1975-2011. Journal of reproductive medicine, The, 2016, 61, 101-8.	0.2	3
57	Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods. Obstetrics and Gynecology, 2015, 126, 823-829.	2.4	55
58	Fertility after Intrauterine Device Removal: A Pilot Study. European Journal of Contraception and Reproductive Health Care, 2015, 20, 223-230.	1.5	29
59	Reply. American Journal of Obstetrics and Gynecology, 2015, 212, 255-256.	1.3	1
60	Contraceptive continuation in Hispanic women. American Journal of Obstetrics and Gynecology, 2015, 212, 312.e1-312.e8.	1.3	11
61	Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception, 2015, 92, 313-318.	1.5	15
62	Adolescent Experiences With Intrauterine Devices: A Qualitative Study. Journal of Adolescent Health, 2015, 57, 381-386.	2.5	46
63	Perceived Weight Gain Among Adolescents Using Contraception. Journal of Pediatric and Adolescent Gynecology, 2015, 28, e70.	0.7	0
64	Pharmacy claims data versus patient self-report to measure contraceptive method continuation. Contraception, 2015, 92, 26-30.	1.5	13
65	The role of contraceptive attributes in women's contraceptive decision making. American Journal of Obstetrics and Gynecology, 2015, 213, 46.e1-46.e6.	1.3	92
66	Positive Testing for <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> and the Risk of Pelvic Inflammatory Disease in IUD Users. Journal of Women's Health, 2015, 24, 354-359.	3.3	34
67	Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration–Approved Duration. Obstetrics and Gynecology, 2015, 125, 599-604.	2.4	72
68	Maternal Age and Risk of Labor and Delivery Complications. Maternal and Child Health Journal, 2015, 19, 1202-1211.	1.5	196
69	Long-term utilization and continuation of intrauterine devices. American Journal of Obstetrics and Gynecology, 2015, 213, 822.e1-822.e6.	1.3	33
70	Three-year continuation of reversible contraception. American Journal of Obstetrics and Gynecology, 2015, 213, 662.e1-662.e8.	1.3	96
71	Performance of a checklist to exclude pregnancy at the time of contraceptive initiation among women with a negative urine pregnancy test. Contraception, 2015, 91, 80-84.	1.5	16
72	Change in Sexual Behavior With Provision of No-Cost Contraception. Obstetrics and Gynecology, 2014, 123, 771-776.	2.4	20

#	Article	IF	CITATIONS
73	The Contraceptive CHOICE Project Round Up. Clinical Obstetrics and Gynecology, 2014, 57, 635-643.	1.1	129
74	A Randomized Trial of Buffered Versus Nonbuffered Lidocaine With Epinephrine for Cervical Loop Excision. Journal of Lower Genital Tract Disease, 2014, 18, 8-12.	1.9	5
75	Association of Age and Parity With Intrauterine Device Expulsion. Obstetrics and Gynecology, 2014, 124, 718-726.	2.4	98
76	Provision of No-Cost, Long-Acting Contraception and Teenage Pregnancy. New England Journal of Medicine, 2014, 371, 1316-1323.	27.0	311
77	Injectable contraception: issues and opportunities. Contraception, 2014, 89, 331-334.	1.5	13
78	Interest in and experience with IUD self-removal. Contraception, 2014, 90, 54-59.	1.5	44
79	Infection: Screening and Management. Journal of Clinical Outcomes Management, 2014, 21, 30-38.	1.7	7
80	Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception, 2013, 88, 503-508.	1.5	93
81	Structured contraceptive counseling provided by the Contraceptive CHOICE Project. Contraception, 2013, 88, 243-249.	1.5	132
82	Sexually Transmitted Infection Prevalence in a Population Seeking No-Cost Contraception. Sexually Transmitted Diseases, 2013, 40, 546-551.	1.7	9
83	Use of the etonogestrel-releasing contraceptive implant. Expert Review of Obstetrics and Gynecology, 2013, 8, 337-344.	0.4	6
84	Twenty-Four–Month Continuation of Reversible Contraception. Obstetrics and Gynecology, 2013, 122, 1083-1091.	2.4	159
85	Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstetrical and Gynecological Survey, 2013, 68, 736-737.	0.4	0
86	Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use. Obstetrics and Gynecology, 2013, 122, 1214-1221.	2.4	103
87	Preventing Unintended Pregnancies by Providing No-Cost Contraception. Obstetrical and Gynecological Survey, 2013, 68, 289-291.	0.4	2
88	Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstetrics and Gynecology, 2013, 121, 585-592.	2.4	58
89	Continuation of the Etonogestrel Implant in Women Undergoing Immediate Postabortion Placement. Obstetrical and Gynecological Survey, 2013, 68, 210-211.	0.4	0
90	Correlates of Dual-Method Contraceptive Use: An Analysis of the National Survey of Family Growth (2006–2008). Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-6.	1.5	44

#	Article	IF	CITATIONS
91	Long-acting reversible contraception for adolescents. Current Opinion in Obstetrics and Gynecology, 2012, 24, 293-298.	2.0	46
92	Contraceptive Failure Rates of Etonogestrel Subdermal Implants in Overweight and Obese Women. Obstetrics and Gynecology, 2012, 120, 21-26.	2.4	155
93	A Randomized Trial of Home Versus Clinic-Based Sexually Transmitted Disease Screening Among Men. Sexually Transmitted Diseases, 2012, 39, 842-847.	1.7	21
94	Predictors of Male Partner Treatment for Sexually Transmitted Infection. Sexually Transmitted Diseases, 2012, 39, 769-775.	1.7	8
95	Continuation of Reversible Contraception in Teenagers and Young Women. Obstetrics and Gynecology, 2012, 120, 1298-1305.	2.4	138
96	Preventing Unintended Pregnancies by Providing No-Cost Contraception. Obstetrics and Gynecology, 2012, 120, 1291-1297.	2.4	402
97	Cervical Cancer Screening: Primum Non Nocere. Annals of Internal Medicine, 2012, 156, 896.	3.9	3
98	Risk of Bacterial Vaginosis in Users of the Intrauterine Device. Sexually Transmitted Diseases, 2012, 39, 217-222.	1.7	63
99	Trends in Contraceptive Use Among Women With Human Immunodeficiency Virus. Obstetrics and Gynecology, 2012, 120, 783-790.	2.4	38
100	Hydrolysis of Secreted Sialoglycoprotein Immunoglobulin A (IgA) in ex Vivo and Biochemical Models of Bacterial Vaginosis. Journal of Biological Chemistry, 2012, 287, 2079-2089.	3.4	62
101	Immediate Postabortion Intrauterine Device Insertion: Continuation and Satisfaction. Women's Health Issues, 2012, 22, e365-e369.	2.0	15
102	Plan B, One Step not taken: politics trumps science yet again. Contraception, 2012, 85, 340-341.	1.5	3
103	Effectiveness of Long-Acting Reversible Contraception. New England Journal of Medicine, 2012, 366, 1998-2007.	27.0	932
104	Continuation of the Etonogestrel Implant in Women Undergoing Immediate Postabortion Placement. Obstetrics and Gynecology, 2012, 120, 1053-1059.	2.4	34
105	Efficacy and Safety of Long-Acting Reversible Contraception. Drugs, 2011, 71, 969-980.	10.9	145
106	Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception, 2011, 83, 340-345.	1.5	30
107	Comparison of contraceptive use between the Contraceptive CHOICE Project and state and national data. Contraception, 2011, 83, 479-485.	1.5	24
108	Perceived racial, socioeconomic and gender discrimination and its impact on contraceptive choice. Contraception, 2011, 84, 273-279.	1.5	33

#	Article	IF	CITATIONS
109	Adherence to dual-method contraceptive use. Contraception, 2011, 84, 252-258.	1.5	29
110	Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception, 2011, 84, 493-498.	1.5	237
111	Comparison of contraceptive method chosen by women with and without a recent history of induced abortion. Contraception, 2011, 84, 571-577.	1.5	45
112	Continuation and Satisfaction of Reversible Contraception. Obstetrics and Gynecology, 2011, 117, 1105-1113.	2.4	448
113	Screening for sexually transmitted infections at home or in the clinic?. Current Opinion in Infectious Diseases, 2011, 24, 78-84.	3.1	24
114	Baseline Correlates of Inconsistent and Incorrect Condom Use Among Sexually Active Women in the Contraceptive CHOICE Project. Sexually Transmitted Diseases, 2011, 38, 1012-1019.	1.7	21
115	Electronic Fetal Monitoring as a Public Health Screening Program: The Arithmetic of Failure. Obstetrics and Gynecology, 2011, 117, 730-731.	2.4	0
116	Severity of bacterial vaginosis and the risk of sexually transmitted infection. American Journal of Obstetrics and Gynecology, 2011, 205, 113.e1-113.e6.	1.3	83
117	Family Planning as a Cost-Saving Preventive Health Service. New England Journal of Medicine, 2011, 364, e37.	27.0	82
118	Women's Knowledge About Intrauterine Contraception. Obstetrics and Gynecology, 2011, 117, 48-54.	2.4	55
119	Home versus clinic-based specimen collection for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> . Expert Review of Anti-Infective Therapy, 2011, 9, 183-194.	4.4	37
120	Home Compared With Clinic-Based Screening for Sexually Transmitted Infections. Obstetrics and Gynecology, 2010, 116, 1311-1318.	2.4	24
121	Association Between Tampon Use and Choosing the Contraceptive Vaginal Ring. Obstetrics and Gynecology, 2010, 115, 735-739.	2.4	17
122	Electronic Fetal Monitoring as a Public Health Screening Program. Obstetrics and Gynecology, 2010, 116, 1397-1400.	2.4	80
123	Home Screening Compared With Clinic-Based Screening for Sexually Transmitted Infections. Obstetrics and Gynecology, 2010, 115, 745-752.	2.4	39
124	The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. American Journal of Obstetrics and Gynecology, 2010, 203, 115.e1-115.e7.	1.3	503
125	Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. Contraception, 2010, 81, 112-116.	1.5	108
126	Type of contraception method used at last intercourse and associations with health risk behaviors among US adolescents. Contraception, 2010, 82, 549-555.	1.5	38

#	Article	IF	CITATIONS
127	The Contraceptive CHOICE Project: Recruiting Women at Highest Risk for Unintended Pregnancy and Sexually Transmitted Infection. Journal of Women's Health, 2010, 19, 2233-2238.	3.3	10
128	Reversible Contraception Update: The Importance of Long-Acting Reversible Contraception. Postgraduate Medicine, 2009, 121, 18-25.	2.0	14
129	Age of sexual debut among US adolescents. Contraception, 2009, 80, 158-162.	1.5	239
130	Reasons for ineffective pre-pregnancy contraception use in patients seeking abortion services. Contraception, 2009, 80, 569-574.	1.5	32
131	Trichomoniasis and Other Sexually Transmitted Infections: Results From the 2001–2004 National Health and Nutrition Examination Surveys. Sexually Transmitted Diseases, 2009, 36, 738-744.	1.7	111
132	Methodology and Analytic Techniques Used in Clinical Research. Obstetrics and Gynecology, 2009, 114, 877-884.	2.4	27
133	Contraceptive choice: how do oral contraceptive users differ from condom users and women who use no contraception?. American Journal of Obstetrics and Gynecology, 2008, 198, e46-e47.	1.3	24
134	Risk Factors for Bladder Injury in Patients With a Prior Hysterotomy. Obstetrics and Gynecology, 2008, 112, 116-120.	2.4	14
135	Viral Sexually Transmitted Infections and Bacterial Vaginosis: 2001–2004 National Health and Nutrition Examination Survey Data. Sexually Transmitted Diseases, 2008, 35, 791-796.	1.7	78
136	Bacterial Vaginosis, Race, and Sexually Transmitted Infections: Does Race Modify the Association?. Sexually Transmitted Diseases, 2008, 35, 363-367.	1.7	66
137	Predicting Failure of a Vaginal Birth Attempt After Cesarean Delivery. Obstetrics and Gynecology, 2007, 109, 800-805.	2.4	63
138	Short Interpregnancy Interval. Obstetrics and Gynecology, 2007, 110, 1075-1082.	2.4	116
139	Predicting Placental Abruption and Previa in Women with a Previous Cesarean Delivery. American Journal of Perinatology, 2007, 24, 299-305.	1.4	18
140	Prevalence of Bacterial Vaginosis. Obstetrics and Gynecology, 2007, 109, 114-120.	2.4	383
141	The Influence of Stress on the Menstrual Cycle among Newly Incarcerated Women. Women's Health Issues, 2007, 17, 202-209.	2.0	57
142	Design of a stage-matched intervention trial to increase dual method contraceptive use (Project) Tj ETQq0 0 0	rgBT ₁ /Over	lock 10 Tf 50
143	Vaginal birth after caesarean delivery: does maternal age affect safety and success?. Paediatric and Perinatal Epidemiology, 2007, 21, 114-120.	1.7	45

¹⁴⁴Discussion: †Acceptability of Emergency Contraception' by Rocca et al. American Journal of Obstetrics
and Gynecology, 2007, 196, e35-e39.1.30

#	Article	IF	CITATIONS
145	Who chooses emergency contraception: a study by Rocca et al. American Journal of Obstetrics and Gynecology, 2007, 196, 90-91.	1.3	0
146	Women at risk for sexually transmitted diseases: correlates of intercourse without barrier contraception. American Journal of Obstetrics and Gynecology, 2007, 197, 474.e1-474.e8.	1.3	21
147	Marijuana Use among Young Women in a Primary Care Setting. Journal of General Internal Medicine, 2007, 22, 826-829.	2.6	10
148	Unplanned Pregnancy. Obstetrics and Gynecology, 2006, 107, 121-127.	2.4	30
149	Pelvic inflammatory disease in adolescents. Current Opinion in Obstetrics and Gynecology, 2006, 18, 503-510.	2.0	77
150	Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease. Obstetrical and Gynecological Survey, 2006, 61, 23-25.	0.4	2
151	Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. American Journal of Obstetrics and Gynecology, 2006, 194, 1283-1289.	1.3	249
152	Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted?. American Journal of Obstetrics and Gynecology, 2006, 195, 1148-1152.	1.3	82
153	Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery?. American Journal of Obstetrics and Gynecology, 2006, 195, 1143-1147.	1.3	105
154	Factors Associated With Increased Charges for Hysterectomy. Obstetrics and Gynecology, 2006, 107, 1057-1063.	2.4	10
155	Safety and Success of Vaginal Birth after Cesarean Delivery in Patients with Preeclampsia. American Journal of Perinatology, 2006, 23, 145-152.	1.4	25
156	The Effect of Prematurity on Vaginal Birth After Cesarean Delivery: Success and Maternal Morbidity. Obstetrics and Gynecology, 2005, 105, 519-524.	2.4	29
157	Adnexal Masses in Pregnancy: Surgery Compared With Observation. Obstetrics and Gynecology, 2005, 105, 1098-1103.	2.4	248
158	Evaluation of Clinical Methods for Diagnosing Bacterial Vaginosis. Obstetrics and Gynecology, 2005, 105, 551-556.	2.4	91
159	Obstetric outcomes in women with two prior cesarean deliveries: Is vaginal birth after cesarean delivery a viable option?. American Journal of Obstetrics and Gynecology, 2005, 192, 1223-1228.	1.3	172
160	Maternal complications with vaginal birth after cesarean delivery: A multicenter study. American Journal of Obstetrics and Gynecology, 2005, 193, 1656-1662.	1.3	263
161	First Trimester Down Syndrome Screening: Public Health Implications. Seminars in Perinatology, 2005, 29, 267-271.	2.5	18
162	Safety and Efficacy of Vaginal Birth After Cesarean Attempts at or Beyond 40 Weeks of Gestation. Obstetrics and Gynecology, 2005, 106, 700-706.	2.4	47

#	Article	IF	CITATIONS
163	Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease. Obstetrics and Gynecology, 2005, 106, 573-580.	2.4	75
164	Research Methodology and Analytic Techniques Used in the Journal Obstetrics & Gynecology. Obstetrics and Gynecology, 2005, 106, 808-812.	2.4	13
165	Diet-controlled gestational diabetes mellitus does not influence the success rates for vaginal birth after cesarean delivery. American Journal of Obstetrics and Gynecology, 2004, 190, 790-796.	1.3	20
166	Actinomyces: Normal Flora or Pathogen?. Obstetrics and Gynecology, 2004, 104, 1132-1133.	2.4	6
167	Condom Use and the Risk of Recurrent Pelvic Inflammatory Disease, Chronic Pelvic Pain, or Infertility Following an Episode of Pelvic Inflammatory Disease. American Journal of Public Health, 2004, 94, 1327-1329.	2.7	60
168	Risk Factors for Febrile Morbidity After Hysterectomy. Obstetrics and Gynecology, 2004, 103, 86-91.	2.4	44
169	Prophylactic antibiotic administration prior to hysterectomy: a quality improvement initiative. Journal of reproductive medicine, The, 2004, 49, 949-54.	0.2	4
170	HPV, cervical neoplasia and smoking: knowledge among colposcopy patients. Journal of reproductive medicine, The, 2004, 49, 965-72.	0.2	5
171	The effect of birth weight on vaginal birth after cesarean delivery success rates. American Journal of Obstetrics and Gynecology, 2003, 188, 824-830.	1.3	140
172	Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. American Journal of Obstetrics and Gynecology, 2003, 188, 141-148.	1.3	106
173	Surgical treatments outcomes project for dysfunctional uterine bleeding (STOP-DUB): design and methods. Contemporary Clinical Trials, 2003, 24, 591-609.	1.9	24
174	Genital Chlamydial Infections. New England Journal of Medicine, 2003, 349, 2424-2430.	27.0	356
175	A randomized comparison of propofol and methohexital as general anesthetics for vacuum abortion. Contraception, 2003, 68, 211-217.	1.5	9
176	Identification and recruitment of low-income pregnant smokers. Addictive Behaviors, 2003, 28, 1497-1505.	3.0	21
177	Route of Delivery as a Risk Factor for Emergent Peripartum Hysterectomy. Obstetrics and Gynecology, 2003, 102, 141-145.	2.4	77
178	Combination of bacterial vaginosis and leukorrhea as a predictor of cervical chlamydial or gonococcal infection. Obstetrics and Gynecology, 2002, 99, 603-607.	2.4	24
179	The economic value of medical research: is it worth the investment?*1. Obstetrics and Gynecology, 2002, 99, 835-840.	2.4	5
180	Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the pelvic inflammatory disease evaluation and clinical health (peach) randomized trial. American Journal of Obstetrics and Gynecology, 2002, 186, 929-937.	1.3	372

#	Article	IF	CITATIONS
181	Urinary tract infections in women with or at risk for human immunodeficiency virus infection. American Journal of Obstetrics and Gynecology, 2002, 187, 581-588.	1.3	20
182	Clinical predictors of cervical intraepithelial neoplasia 2 or greater in women with mildly abnormal Pap smears. Journal of reproductive medicine, The, 2002, 47, 891-6.	0.2	3
183	www.ahrq.gov/clinic/uspstrix.htm, through the National Guideline Clearinghouse (www.guideline.gov), or in print through the AHRQ Clearinghouse (1-800-358-9295).22The U.S. Preventive Services Task Force recommendations based on this evidence review can be found in Screening for Bacterial Vaginosis in Pregnancy: Recommendations and Rationale, available elsewhere	3.0	110
184	Efficacy of Clindamycin Vaginal Ovule (3-Day Treatment) vs. Clindamycin Vaginal Cream (7-Day) Tj ETQqO O O	gBT /Overlo 1.5	ock 10 Tf 50 6 37
185	A Randomized Trial of Azithromycin Versus Amoxicillin for the Treatment of Chlamydia trachomatis in pregnancy. Infectious Diseases in Obstetrics and Gynecology, 2001, 9, 197-202.	1.5	50
186	Human papillomavirus–associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 2001, 184, 584-590.	1.3	80
187	Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. American Journal of Obstetrics and Gynecology, 2001, 184, 856-864.	1.3	106
188	Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. American Journal of Obstetrics and Cynecology, 2001, 185, 121-127.	1.3	50
189	Association of Lower Genital Tract Inflammation With Objective Evidence of Endometritis. Infectious Diseases in Obstetrics and Gynecology, 2000, 8, 83-87.	1.5	36
190	Ambulatory Gynecology. JAMA - Journal of the American Medical Association, 2000, 283, 2630.	7.4	1
191	Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics and Gynecology, 2000, 95, 227-231.	2.4	30
192	Epidemiologic Issues of Sexually Transmitted Diseases in Sexual Assault Victims. Obstetrical and Gynecological Survey, 2000, 55, 51.	0.4	52
193	Positive cone biopsy specimen margins in women infected with the human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 1999, 181, 1395-1399.	1.3	19
194	Strength of indication for cesarean delivery: Comparison of private physician versus resident service labor management. American Journal of Obstetrics and Gynecology, 1999, 181, 435-439.	1.3	15
195	Prevalence of Cervical Intraepithelial Neoplasia Grade 2 or 3 in Patients with Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesions. Journal of Lower Genital Tract Disease, 1999, 3, 196-200.	1.9	Ο
196	Vulvar Vestibulitis:Is It a Defined and Treatable Entity?. Clinical Obstetrics and Gynecology, 1999, 42, 945.	1.1	12
197	Cost-Effectiveness Analysis: An Introductory Guide for Clinicians. Obstetrical and Gynecological Survey, 1999, 54, 663-672.	0.4	14
198	Use of the transtheoretical model for behavioral change in women's health. Women's Health Issues, 1998, 8, 304-309.	2.0	7

#	Article	IF	CITATIONS
199	A Prevalence Survey of Abuse and Screening for Abuse in Urgent Care Patients. Obstetrics and Gynecology, 1998, 91, 511-514.	2.4	31
200	Observational Studies. Clinical Obstetrics and Gynecology, 1998, 41, 235-244.	1.1	25
201	Screening and Diagnostic Testing. Clinical Obstetrics and Gynecology, 1998, 41, 267-274.	1.1	11
202	Power and Sample Size. Clinical Obstetrics and Gynecology, 1998, 41, 257-266.	1.1	1
203	Prognostic value of clinical variables in ovarian cancer. Journal of Clinical Epidemiology, 1997, 50, 501-505.	5.0	20
204	Systematic reviews of medical evidence: The use of meta-analysis in obstetrics and gynecology. Obstetrics and Gynecology, 1997, 89, 628-633.	2.4	19
205	Endovaginal sonography for the diagnosis of upper genital tract infection. Obstetrics and Gynecology, 1997, 90, 54-57.	2.4	55
206	Research Design and Methods of Quantitative Synthesis of Medical Evidence. Obstetrics and Gynecology, 1997, 90, 473-478.	2.4	10
207	Violence against Women: Provider Barriers to Intervention in Emergency Departments. Academic Emergency Medicine, 1997, 4, 297-300.	1.8	97
208	Bacterial vaginosis as a risk factor for upper genital tract infection. American Journal of Obstetrics and Gynecology, 1997, 177, 1184-1187.	1.3	145
209	Oral contraception and the recognition of endometritis. American Journal of Obstetrics and Gynecology, 1997, 176, 580-585.	1.3	57
210	S-Phase Fraction, p53, and HER-2/neu Status as Predictors of Nodal Metastasis in Early Vulvar Cancer. Gynecologic Oncology, 1997, 67, 200-202.	1.4	26
211	Laboratory evaluation of acute upper genital tract infection. Obstetrics and Gynecology, 1996, 87, 730-736.	2.4	64
212	College Women and Condom Use, 1975–1995. New England Journal of Medicine, 1996, 335, 211-211.	27.0	2
213	Battering in pregnancy: An assessment of two screening methods. Obstetrics and Gynecology, 1995, 85, 321-325.	2.4	175
214	?. Obstetrics and Gynecology, 1995, 86, 302-305.	2.4	13
215	Diagnostic Evaluation of Pelvic Inflammatory Disease. Infectious Diseases in Obstetrics and Gynecology, 1994, 2, 38-48.	1.5	10
216	The impact of symptoms and comorbidity on prognosis in stage IB cervical cancer. American Journal of Obstetrics and Gynecology, 1993, 169, 598-604.	1.3	10

#	Article	IF	CITATIONS
217	Oligohydramnios. Obstetrical and Gynecological Survey, 1991, 46, 325-339.	0.4	44
218	Knowledge and intention to use long-acting reversible contraception among university students. Journal of American College Health, 0, , 1-4.	1.5	0